<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974776</url>
  </required_header>
  <id_info>
    <org_study_id>C3651002</org_study_id>
    <secondary_id>FIP</secondary_id>
    <secondary_id>Japanese Ph1</secondary_id>
    <nct_id>NCT03974776</nct_id>
  </id_info>
  <brief_title>Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE-DOSE, SUBCUTANEOUS ADMINISTRATION OF PF-06946860 TO HEALTHY ADULT JAPANESE PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      PF-06946860 in healthy adult Japanese participants following single dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of participants experiencing AE</measure>
    <time_frame>Up to 20 weeks post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed PF-06946860 Concentration (Cmax)</measure>
    <time_frame>Up to 20 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable PF-06946860 Concentration (AUClast)</measure>
    <time_frame>Up to 20 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed PF-06946860 Concentration (Tmax)</measure>
    <time_frame>Up to 20 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-06946860 Half-Life (t1/2)</measure>
    <time_frame>Up to 20 weeks post-dose, as data permit</time_frame>
    <description>Time measured for the PF-06946860 concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of development of ADA, and if necessary NAb, against PF-06946860</measure>
    <time_frame>Up to 20 weeks post-dose, as data permit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-06946860</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of PF-06946860</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06946860</intervention_name>
    <description>PF-06946860 administered subcutaneously</description>
    <arm_group_label>PF-06946860</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy female subjects of nonchildbearing potential and/or male subjects who, at the
             time of screening, are between the ages of 18 and 55 years, inclusive

          -  Body mass index (BMI) within 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110
             lb)

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study

          -  Subjects enrolling as Japanese must have four biologically Japanese grandparents born
             in Japan.

        Key Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing.

          -  History of allergic reactions to diagnostic or therapeutic protein or human albumin.

          -  History of recurrent infections or active infection within 28 days of screening.

          -  Exposure to live vaccines within 28 days of screening.

          -  History of regular alcohol consumption or positive drug test

          -  Treatment with an investigational drug within 30 days (or as determined by the local
             requirement) or 5 half lives preceding the first dose of IP (whichever is longer).

          -  Fertile male subjects who are unwilling or unable to use a highly effective method of
             contraception for the duration of the study and for at least 28 days after the last
             dose.

          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or
             5 half lives (whichever is longer) prior to the first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials LLC-Clinical Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3651002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

